BioSpace News Archive

What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital

How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding.

December 19, 2023
·
1 min read
·
BioSpace Insights
Bluebird Looks to Raise $250M After Lukewarm Reception of SCD Gene Therapy

Cash-strapped bluebird bio is aiming to raise a quarter of a billion dollars through two funding vehicles—a public offering and a deal with finance firm Alterna—to support its general and commercialization operations.

December 19, 2023
·
3 min read
·
Tristan Manalac
Business

Gilead, Compugen Ink Potential $848M Deal for Preclinical Immunotherapy

Israel-based cancer immunotherapy company Compugen will receive $60 million upfront from Gilead for the license to its antibody, which blocks the interaction between the IL-18 binding protein and IL-18.

December 19, 2023
·
2 min read
·
Tyler Patchen
Policy

Activist Investor Icahn Targets Illumina Board Amid GRAIL Divestiture

Carl Icahn is seeking to get rid of “legacy conflicted directors” on Illumina’s board following the announcement that GRAIL will be divested after a drawn out antitrust battle with regulators.

December 19, 2023
·
2 min read
·
Kate Goodwin
Policy

Failed Illumina and Sanofi Deals Shine Light on FTC Antitrust Crackdown

Companies and patients alike are questioning the Federal Trade Commission’s challenges to various biopharma agreements.

December 19, 2023
·
3 min read
·
Nadia Bey
Policy

5 FDA Decisions to Watch in Q1

Iovance’s lifileucel for advanced melanoma and Madrigal’s resmetirom for nonalcoholic steatohepatitis are just a couple of the key decisions on the FDA’s docket this quarter.

December 19, 2023
·
6 min read
·
Heather McKenzie
Drug Development

GSK’s Jemperli-Zejula Combo Aces Phase III Trial in Endometrial Cancer

The combination of Jemperli and chemotherapy followed by Zejula improved progression-free survival in a late-stage study of patients with advanced or recurrent endometrial cancer.

December 19, 2023
·
2 min read
·
Tristan Manalac
Novo Nordisk Foundation Pumps $260M into Vaccines for Respiratory Diseases

The new research and vaccine initiative seeks to develop immunizations against influenza, tuberculosis and other deadly respiratory diseases.

December 19, 2023
·
2 min read
·
Tristan Manalac
Policy

Market for CAR-Ts Still Bright Despite FDA Cancer Safety Review

Shares of several biopharma companies in the CAR-T space dropped after the FDA’s announcement, but analysts remain optimistic about the sector’s future.

December 19, 2023
·
5 min read
·
Jill Neimark
Q&A: JLL Analyst Mark Bruso on Biopharma Venture Capital Activity

With uncertainty rocking the venture capital market in the biotech and pharma industry, analysts from JLL give their thoughts on what the market looks like and where it may be heading.

December 19, 2023
·
2 min read
·
Tyler Patchen